MA55625A - Compositions et méthodes d'administration de produits thérapeutiques - Google Patents

Compositions et méthodes d'administration de produits thérapeutiques

Info

Publication number
MA55625A
MA55625A MA055625A MA55625A MA55625A MA 55625 A MA55625 A MA 55625A MA 055625 A MA055625 A MA 055625A MA 55625 A MA55625 A MA 55625A MA 55625 A MA55625 A MA 55625A
Authority
MA
Morocco
Prior art keywords
administration
compositions
methods
therapeutic products
therapeutic
Prior art date
Application number
MA055625A
Other languages
English (en)
Inventor
Archana Belle
Stephanie Tagliatela
Original Assignee
Encoded Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encoded Therapeutics Inc filed Critical Encoded Therapeutics Inc
Publication of MA55625A publication Critical patent/MA55625A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
MA055625A 2019-04-12 2020-04-10 Compositions et méthodes d'administration de produits thérapeutiques MA55625A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962833447P 2019-04-12 2019-04-12

Publications (1)

Publication Number Publication Date
MA55625A true MA55625A (fr) 2022-02-16

Family

ID=72750879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055625A MA55625A (fr) 2019-04-12 2020-04-10 Compositions et méthodes d'administration de produits thérapeutiques

Country Status (17)

Country Link
US (1) US20220168449A1 (fr)
EP (1) EP3952924A4 (fr)
JP (1) JP2022526425A (fr)
KR (1) KR20220007601A (fr)
CN (1) CN114430684A (fr)
AU (1) AU2020272980A1 (fr)
BR (1) BR112021020421A2 (fr)
CA (1) CA3136646A1 (fr)
CL (1) CL2021002635A1 (fr)
CO (1) CO2021013548A2 (fr)
EA (1) EA202192801A1 (fr)
IL (1) IL287137A (fr)
MA (1) MA55625A (fr)
MX (1) MX2021012527A (fr)
SG (1) SG11202111195VA (fr)
TW (1) TW202104596A (fr)
WO (1) WO2020210633A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103102WA (en) 2018-09-26 2021-04-29 California Inst Of Techn Adeno-associated virus compositions for targeted gene therapy
EP4291654A2 (fr) 2021-02-12 2023-12-20 Alnylam Pharmaceuticals, Inc. Compositions d'arni de superoxyde dismutase 1 (sod1) et procédés d'utilisation correspondants pour traiter ou prévenir des maladies neurodégénératives associées à la superoxyde dismutase 1 (sod1)
WO2025245481A1 (fr) * 2024-05-24 2025-11-27 The Regents Of The University Of California Procédés et matériel pour traiter des affections cardiaques

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241854A1 (en) * 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
WO2007044627A2 (fr) * 2005-10-06 2007-04-19 Sloan Kettering Institute For Cancer Research Compositions et methodes d'administration d'arn interferant
CN101460621B (zh) * 2006-06-07 2016-01-27 建新公司 肌萎缩性侧索硬化和其他脊髓失调症的基因治疗
PT3252161T (pt) * 2007-06-06 2022-02-01 Genzyme Corp Terapia genética para doenças do armazenamento lisossomal
JP5879256B2 (ja) * 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
BR112015027336A2 (pt) * 2013-05-01 2017-09-26 Genzyme Corp composições e processos para tratamento de atrofia muscular espinhal
PT3024497T (pt) * 2013-07-26 2021-08-23 Univ Iowa Res Found Métodos e composições para o tratamento de doenças cerebrais
EP3151846A4 (fr) * 2014-06-05 2017-12-27 Sangamo BioSciences, Inc. Méthodes et compositions de conception de nucléase
CN112410338A (zh) * 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
US10123969B2 (en) * 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
US12070510B2 (en) * 2016-02-05 2024-08-27 Emory University Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
EP3548616A4 (fr) * 2016-12-01 2020-05-13 Sangamo Therapeutics, Inc. Modulateurs de tau et procédés et compositions pour leur administration
EP3585807A1 (fr) * 2017-02-22 2020-01-01 CRISPR Therapeutics AG Matériaux et procédés pour le traitement de la maladie de parkinson à début précoce (park1) et d'autres états pathologiques ou troubles associés au gène alpha (snca)
BR112019023303A2 (pt) * 2017-05-11 2020-06-16 The Trustees Of The University Of Pennsylvania Terapia de gene para lipofuscinoses ceroides neuronais
CN118956965A (zh) * 2017-05-19 2024-11-15 编码治疗公司 高活性调控元件
WO2020243651A1 (fr) * 2019-05-29 2020-12-03 Encoded Therapeutics, Inc. Compositions et procédés de régulation sélective de gènes

Also Published As

Publication number Publication date
KR20220007601A (ko) 2022-01-18
US20220168449A1 (en) 2022-06-02
EA202192801A1 (ru) 2022-02-24
CA3136646A1 (fr) 2020-10-15
MX2021012527A (es) 2022-01-06
IL287137A (en) 2021-12-01
CO2021013548A2 (es) 2022-01-28
CL2021002635A1 (es) 2022-07-15
AU2020272980A1 (en) 2021-11-04
EP3952924A4 (fr) 2023-05-24
WO2020210633A1 (fr) 2020-10-15
SG11202111195VA (en) 2021-11-29
JP2022526425A (ja) 2022-05-24
CN114430684A (zh) 2022-05-03
BR112021020421A2 (pt) 2021-12-21
TW202104596A (zh) 2021-02-01
WO2020210633A8 (fr) 2021-09-30
EP3952924A1 (fr) 2022-02-16

Similar Documents

Publication Publication Date Title
MA56541A (fr) Plateformes, compositions et méthodes d'administration de composés thérapeutiques
EP3924481A4 (fr) Compositions et méthodes de traitement d'hémoglobinopathies
ZA202110597B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3813853A4 (fr) Compositions pour l'administration de médicaments et leurs méthodes d'utilisation
EP3840730A4 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
EP4034253A4 (fr) Compositions et méthodes pour accroître l'efficacité d'immunothérapies et de vaccins
EP3355954A4 (fr) Méthodes et compositions d'administration
IL285428A (en) Long lasting disinfectant cleaning compositions and methods of use thereof
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
EP4297784A4 (fr) Compositions et méthodes d'administration thérapeutique
EP3880688A4 (fr) Préparations et compositions d'oligosaccharides
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
EP3817747A4 (fr) Administration ciblée d'agents thérapeutiques à des adipocytes humains
EP3474857A4 (fr) Compositions et méthodes de libération d'agents thérapeutiques
IL273125A (en) Pharmaceutical formulations of cyclic oligomer of abiraterone and methods of making and taking them
EP3407925A4 (fr) Produits tissulaires f taux de support et méthodes d'utilisation
EP3908251A4 (fr) Compositions d'administration de produits pharmaceutiques et utilisations correspondantes
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
EP3713569A4 (fr) Compositions et méthodes d'administration d'une composition inhibitrice d'yap1/wwrt1 et d'une composition inhibitrice de gls1
MA55291A (fr) Procédé de fabrication d'extraits bactériens stables et leur utilisation en tant que produits pharmaceutiques
EP3768242A4 (fr) Méthodes et compositions pour l'administration ciblée d'agents actifs et d'agents immunomodulateurs à des ganglions lymphatiques
EP3746058C0 (fr) Compositions et méthodes d'amélioration de la biodisponibilité de 5-hydroxytryptophane
EP3203995A4 (fr) Compositions et méthodes d'administration d'agents thérapeutiques
MA55568A (fr) Compositions pharmaceutiques orodispersibles d'apixaban
JOP20190057A1 (ar) تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية